Hedeer Fredrik, Oddstig Jenny, Hallgrimson Páll, Fagher Katarina
Department of Clinical Physiology and Nuclear Medicine, Lund University, Skåne University Hospital, Entrégatan 7, Lund, S-221 85, Sweden.
Department of Medical Radiation Physics, Lund University, Skåne University Hospital, Lund, Sweden.
EJNMMI Rep. 2025 Sep 1;9(1):31. doi: 10.1186/s41824-025-00267-3.
A patient with multiple endocrine neoplasia 2A (MEN2A) and a suspicion of metastasized pheochromocytoma, underwent multi-molecular positron emission tomography (PET) imaging with the recently presented radiopharmaceutical [F]-metafluorobenzylguanidine (mFBG), [Ga]Ga-DOTA-TOC and [F]F-dihydroxyphenylalanine (DOPA) as well as scintigraphy with [I]-metaiodobenzylguanidine (mIBG). The methods showed different diagnostic performance, with the highest number of suspected malignant lesions detected by [F]-mFBG-PET, and revealed insights into tumour heterogeneity.
一名患有2A型多发性内分泌腺瘤病(MEN2A)且怀疑有转移性嗜铬细胞瘤的患者,接受了使用最近推出的放射性药物[F] - 间氟苄胍(mFBG)、[Ga]Ga - DOTA - TOC和[F]F - 二羟基苯丙氨酸(DOPA)的多分子正电子发射断层扫描(PET)成像以及使用[I] - 间碘苄胍(mIBG)的闪烁扫描。这些方法显示出不同的诊断性能,[F] - mFBG - PET检测到的疑似恶性病变数量最多,并揭示了肿瘤异质性的相关情况。